INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer's disease.
- Resource Type
- Article
- Source
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2021 Supplement S9, Vol. 17, p1-1, 1p
- Subject
- Language
- ISSN
- 15525260